The aim of the study is to enhance knowledge about variant-drug matches and harmonizing access to genomic testing and off-label use in Norway. Eligible patients have an advanced malignancy progressing on standard treatment, acceptable performance status and organ function, with no other suitable clinical trial available in Norway. 

Eligible patients for detailed molecular diagnostics including extended gene panel analysis covering 523 genes, reimbursed by the Norwegian Health Care System, can participate in IMPRESS-Norway. If the molecular diagnostics identifies a potentially targetable molecular alteration and a matching drug is available in the IMPRESS-Norway drug portfolio then the patient can be included into a IMPRESS-Norway treatment cohort.